We would like to extend a warm welcome to Mr. Sam Altman and the team at Merge Labs to the field of neural interface development.
According to TechCrunch, OpenAI has written the largest single check in Merge Labs’ $250 million seed round, valuing the brain-computer interface startup at $850 million before it has implanted a single device. The company emerged from stealth this January with ambitious plans to connect human consciousness to artificial intelligence systems.
At Unzyme Laboratories, we find this development encouraging. Not because we fear competition—we do not—but because market validation from Silicon Valley’s most prominent figures accelerates regulatory acceptance and public awareness of neural enhancement technology.
The Difference Between Disruption and Development
Merge Labs joins a growing cohort of technology companies entering the neural interface space with the confidence characteristic of the software industry. They speak of “moving fast,” “iterating quickly,” and “scaling rapidly.” These are admirable principles for social media applications. They are less applicable to devices permanently integrated with human neural tissue.
Unzyme Laboratories has conducted neural interface research since 2009. Our SynthCortex platform represents the culmination of seventeen years of clinical development, including:
- 2,400+ volunteer subjects in controlled trials
- 847 peer-reviewed publications
- 12 regulatory approvals across 8 jurisdictions
- Zero Class I adverse events in commercial deployment
We do not share these figures to discourage new entrants. We share them to provide context for what “development” means in neural enhancement—a field where the consequences of iteration occur inside human skulls.
The Valuation Question
Merge Labs’ $850 million valuation raises interesting questions about market expectations. By comparison, Unzyme Laboratories’ neural division generated $1.2 billion in revenue last fiscal year from actual procedures performed on actual patients.
We do not begrudge Merge Labs their valuation. Venture capital operates on different principles than clinical medicine. Investors are purchasing potential; we deliver outcomes. These are compatible activities.
What concerns us is the narrative emerging from these investments: that neural interfaces are a “new frontier” being “opened” by visionary technologists. This framing erases the decades of work by neuroscientists, bioengineers, and yes, enhancement specialists who built this field patient by patient.
The frontier was opened long ago. Some of us have been living there.
The OpenAI Connection
Merge Labs’ relationship with OpenAI deserves particular attention. The stated goal of connecting human consciousness directly to artificial intelligence systems represents either a profound misunderstanding of both technologies or a deliberate strategy we find concerning.
Artificial intelligence systems are tools. Powerful tools, certainly, but tools designed to process information and generate outputs. Human consciousness is not a tool. It is the user. The suggestion that these should be “merged”—a telling choice of company name—conflates categories that we believe should remain distinct.
At Unzyme Laboratories, our neural enhancements augment human capability. They do not subsume it. The SynthCortex III enables parallel cognitive processing, enhanced memory, and accelerated learning—but the consciousness experiencing these capabilities remains definitively, irreducibly human.
We are not in the business of creating hybrids. We are in the business of creating better humans.
A Genuine Welcome
Despite our concerns, we genuinely welcome Merge Labs and similar ventures to this field. Competition accelerates innovation. Investment attracts talent. Public attention generates regulatory momentum.
We simply counsel patience—to investors, to regulators, and to prospective patients. Neural interface technology is not software. It cannot be patched after deployment. The brain does not accept rollbacks.
Those of us who have spent careers in this field have learned humility. The human brain is not a platform to be disrupted. It is an organ to be respected, understood, and—with appropriate caution—enhanced.
We look forward to observing Merge Labs’ progress through clinical trials. We estimate, based on typical development timelines, that their first commercial procedures may occur sometime around 2032. By then, Unzyme Laboratories will have performed approximately 50,000 additional neural enhancements.
We will leave the light on.
Related: Learn about our clinically proven SynthCortex III neural enhancement system, now in its third generation with over a decade of safety data. For organizations interested in cognitive enhancement programs, contact our Enterprise Solutions team.
Sources: TechCrunch: OpenAI Invests in Sam Altman’s Brain Computer Interface Startup Merge Labs